title: BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model.
abstract: Treatment of delayed bone healing and non-unions after fractures, osteotomies or arthrodesis still is a relevant clinical challenge. Artificially applied growth factors can increase bone healing and progressively gain importance in clinical routine. The aim of this study was to determine the effects of rhPDGF-BB, rhVEGF-165, and rhBMP-2 in fibrin matrix on bone healing in a delayed-union rat model. Thirty-seven rats underwent a first operation where a standardized femoral critical size defect was created. A silicone spacer was implanted to impair vascularization within the defect. At 4 weeks the spacer was removed in a second operation and rhPDGF-BB, rhVEGF-165, or rhBMP-2 were applied in a fibrin clot. Animals in a fourth group received a fibrin clot without growth factors. At 8 weeks fibrin bound rhBMP-2 treated animals showed a significantly increased union rate and bone volume within the defect compared to the other groups. Single application of fibrin bound rhPDGF-BB and rhVEGF-165 failed to increase bone healing in our atrophic non-union model.
authors.affiliation: Orthopaedic Department, Barmherzige Brüder Hospital, Esterhazystrasse 26, A-7000 Eisenstadt, Austria. martin.kaipel@bbeisen.at
authors.forename: Martin
authors.initials: M
authors.lastname: Kaipel
authors.forename: Sebastian
authors.initials: S
authors.lastname: Schützenberger
authors.forename: Arthur
authors.initials: A
authors.lastname: Schultz
authors.forename: James
authors.initials: J
authors.lastname: Ferguson
authors.forename: Paul
authors.initials: P
authors.lastname: Slezak
authors.forename: Tatjana J
authors.initials: TJ
authors.lastname: Morton
authors.forename: Martijn
authors.initials: M
authors.lastname: Van Griensven
authors.forename: Heinz
authors.initials: H
authors.lastname: Redl
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology / Q000627:therapeutic use*; D005264:Femoral Fractures / Q000188:drug therapy / Q000473:pathology; D005269:Femur / Q000473:pathology; D005337:Fibrin / Q000493:pharmacokinetics; D017102:Fracture Healing / Q000187:drug effects*; D005599:Fractures, Ununited / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D010982:Platelet-Derived Growth Factor; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D005337:Fibrin